Trimarco Valentina, Izzo Raffaele, Migliore Teresa, Rozza Francesco, Marino Marina, Manzi Maria Virginia, De Marco Marina, de Simone Giovanni, De Luca Nicola
Hypertension Research Center, Federico II University Hospital, via S. Pansini 5, bld. 2, 80131, Naples, Italy.
High Blood Press Cardiovasc Prev. 2015 Mar;22(1):55-9. doi: 10.1007/s40292-014-0065-0. Epub 2014 Jun 24.
The recommendation to start antihypertensive therapy with diuretics (D) might produce delay in blood pressure (BP) control and, possibly, increase cost/benefit ratio.
We evaluate the effects of D in relation to the administration of other anti-hypertensive medications, in clinical practice.
General practitioners recruited 2,409 hypertensive patients with indication to antihypertensive therapy, who were randomized to start treatment with chlorthalidone (12.5-25 mg daily, group D) or any other single medications (excluding thiazides, group A). The patients have been followed for at least 2 years.
Among the 2,409 patients recruited (42.5 % women), 1,205 were randomized in group D and 1,204 in group A, of which 1,051 (or 87 %) and 1026 (or 85 %) respectively, completed the study. The number of patients in optimal BP control was similar in the two groups (65.0 vs 64.0 %; p = NS). During follow-up, the group D had prescribed a slightly greater number of medications compared to the group A who added D as second line (2.3 vs 2.1; p < 0.0001). In particular group D took more β-blockers (27.1 vs 14.9 %; p < 0.0001) with a similar number of patients in optimal BP control (64.35 vs 63.9 %; p = NS).
The beginning of antihypertensive therapy with diuretics is more often subject to the addition of one or more medications to obtain an effective blood pressure control, since the diuretic administered at the beginning of the antihypertensive regimen is only rarely associated with optimal blood pressure control.
推荐使用利尿剂(D)开始抗高血压治疗可能会导致血压(BP)控制延迟,并可能增加成本效益比。
我们在临床实践中评估了D与其他抗高血压药物给药相关的效果。
全科医生招募了2409名有抗高血压治疗指征的高血压患者,将其随机分为开始使用氯噻酮治疗组(每日12.5 - 25毫克,D组)或任何其他单一药物治疗组(不包括噻嗪类,A组)。对患者进行了至少2年的随访。
在招募的2409名患者中(42.5%为女性),1205名被随机分配到D组,1204名被分配到A组,其中分别有1051名(或87%)和1026名(或85%)完成了研究。两组中血压控制在最佳水平的患者数量相似(65.0%对64.0%;p = 无显著性差异)。在随访期间,D组比将D作为二线药物添加的A组开具的药物数量略多(2.3对2.1;p < 0.0001)。特别是D组服用更多的β受体阻滞剂(27.1%对14.9%;p < 0.0001),而血压控制在最佳水平的患者数量相似(64.35%对63.9%;p = 无显著性差异)。
使用利尿剂开始抗高血压治疗更常需要添加一种或多种药物以实现有效的血压控制,因为在抗高血压治疗方案开始时使用的利尿剂很少能使血压达到最佳控制。